ZBIO
Zenas BioPharmaยทNASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About ZBIO
Zenas Biopharma, Inc.
A clinical-stage global biopharmaceutical company committed to becoming a leader in the development and commercialization of transformative immunology-based therapies for patients in need
852 Winter Street, Suite 250, Waltham, MA 02451
--
Zenas BioPharma, Inc., was originally incorporated in Cayman on November 12, 2019 under the name Zenas BioPharma (Cayman) Limited. On August 2, 2023, the company was incorporated in Delaware and simultaneously changed its name from Zenas BioPharma (Cayman) Limited to Zenas BioPharma, Inc. They are a clinical-stage global biopharmaceutical company dedicated to developing and commercializing immune-based transformative therapies for patients in need. With the growing understanding of the pathogenesis of autoimmune diseases and the expansion of promising immunology-based pharmacological targets, they are building a biopharmaceutical company focused on immunology and inflammation (" I & I ").
Company Financials
EPS
ZBIO has released its 2025 Q3 earnings. EPS was reported at -1.22, versus the expected 0.38, missing expectations. The chart below visualizes how ZBIO has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
